Host |
Monospecific Mouse |
Klon |
ZM33 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Bone marrow or tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human ITGB3 protein fragment (aa 385-490) |
Lokalisation |
Cell membrane/Cytoplasm |
CD61
|
Zeta Corporation |
ZM33 |
1 ml |
Concentrate |
CE/IVD |
Z2337ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM33 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Bone marrow or tonsil. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human ITGB3 protein fragment (aa 385-490) |
Lokalisation |
Cell membrane/Cytoplasm |
CD61
|
Zeta Corporation |
ZM33 |
7 ml |
Ready-to-use |
CE/IVD |
Z2337MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM33 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Bone marrow or tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human ITGB3 protein fragment (aa 385-490) |
Lokalisation |
Cell membrane/Cytoplasm |
CD61
|
Zeta Corporation |
ZM33 |
0.5 ml |
Concentrate |
CE/IVD |
Z2337MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM33 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Bone marrow or tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human ITGB3 protein fragment (aa 385-490) |
Lokalisation |
Cell membrane/Cytoplasm |
CD61
|
Zeta Corporation |
ZM33 |
0.1 ml |
Concentrate |
CE/IVD |
Z2337MT |
-
|
Host |
Mouse |
Klon |
Y2/51 |
Format |
Purified |
Methode |
FL, F, P |
Isotyp |
Mouse IgG1 |
Verdünnung |
PHA stimulated peripheral blood cells |
CD61 (Integrin beta3)
|
Zytomed Systems GmbH |
Y2/51 |
100 µg |
Purified |
RUO |
603-2368 |
-
|
Host |
Mouse |
Klon |
Y2/51 |
Format |
Purified |
Methode |
FL, F, P, WB |
Isotyp |
Mouse IgG1 |
Verdünnung |
PHA stimulated peripheral blood cells |
CD61 (Integrin beta3)
|
Zytomed Systems GmbH |
Y2/51 |
200 µg |
Purified |
RUO |
603-2369 |
-
|
Host |
Mouse |
Klon |
AK-6 |
Format |
Purified |
Methode |
F, P, WB, FL |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:500 - 1:2000 (P) |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human platelet membrane glycoproteins |
CD62 (P-Selectin)
|
Zytomed Systems GmbH |
AK-6 |
200 µg |
Purified |
RUO |
603-1286 |
-
|
Host |
Mouse |
Klon |
AK-6 |
Format |
Purified |
Methode |
FL, F, P, IF, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:500 - 1:2000 (P) |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human platelet membrane glycoproteins |
CD62 (P-Selectin)
|
Zytomed Systems GmbH |
AK-6 |
100 µg |
Purified |
RUO |
603-1287 |
-
|
Host |
Mouse |
Klon |
CL2/6 |
Format |
Purified |
Methode |
F, FL, IF |
Isotyp |
Mouse IgG2a |
CD62E (E-Selectin)
|
Zytomed Systems GmbH |
CL2/6 |
100 µg |
Purified |
RUO |
603-1294 |
-
|
Host |
Mouse |
Klon |
1.2B6 |
Format |
Purified |
Methode |
FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human E-Selectin (ELAM-1) |
CD62E /CD62P - FITC
|
Zytomed Systems GmbH |
1.2B6 |
100 µg |
Purified |
RUO |
603-1298C |
-
|
Host |
Mouse |
Klon |
NK-I/C3 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Melanoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
CD63
|
Diagnostic Biosystems |
NK-I/C3 |
1 ml |
Concentrate |
CE/IVD |
MOB301 |
-
|
Host |
Mouse |
Klon |
NK-I/C3 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Melanoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
CD63
|
Diagnostic Biosystems |
NK-I/C3 |
0.1 ml |
Concentrate |
CE/IVD |
MOB301-01 |
-
|
Host |
Mouse |
Klon |
NK-I/C3 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Melanoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
CD63
|
Diagnostic Biosystems |
NK-I/C3 |
0.5 ml |
Concentrate |
CE/IVD |
MOB301-05 |
-
|
Host |
Mouse |
Klon |
80H3 |
Format |
Purified |
Methode |
F, FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
CML leukocytes |
CD66b
|
Zytomed Systems GmbH |
80H3 |
200 µg |
Purified |
RUO |
603-1320 |
-
|
Host |
Rabbit |
Klon |
SP251 |
Format |
Concentrate |
Methode |
P, FL |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Verdünnung |
Synthetic peptide within Human CD68 aa 100-200 (internal sequence) |
Lokalisation |
Cytoplasmic membrane |
CD68
|
Zytomed Systems GmbH |
SP251 |
1 ml |
Concentrate |
RUO |
503-5514 |
-
|
Host |
Mouse |
Klon |
PG-M1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Fast Enzyme or other Enzymes |
Positivkontrolle |
Tonsil |
Verdünnung |
1:10 - 1:40 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
CD68
|
Diagnostic Biosystems |
PG-M1 |
1 ml |
Concentrate |
CE/IVD |
MOB094 |
-
|
Host |
Mouse |
Klon |
PG-M1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Fast Enzyme or other Enzymes |
Positivkontrolle |
Tonsil |
Verdünnung |
1:10 - 1:40 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
CD68
|
Diagnostic Biosystems |
PG-M1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB094-01 |
-
|
Host |
Mouse |
Klon |
PG-M1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Fast Enzyme or other Enzymes |
Positivkontrolle |
Tonsil |
Verdünnung |
1:10 - 1:40 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
CD68
|
Diagnostic Biosystems |
PG-M1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB094-05 |
-
|
Host |
Mouse |
Klon |
PG-M1 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Fast Enzyme or other Enzymes |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
CD68
|
Diagnostic Biosystems |
PG-M1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM065 |
-
|
Host |
Mouse |
Klon |
KP1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil, lymph node, spleen. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Subcellular fraction of human alveolar macrophages |
Lokalisation |
Cytoplasm |
CD68
|
Zeta Corporation |
KP1 |
1.0 ml |
Concentrate |
CE/IVD |
Z2071ML |
-
|
Host |
Mouse |
Klon |
KP1 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil, lymph node, spleen. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Subcellular fraction of human alveolar macrophages |
Lokalisation |
Cytoplasm |
CD68
|
Zeta Corporation |
KP1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2071MP |
-
|
Host |
Mouse |
Klon |
KP1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil, lymph node, spleen. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Subcellular fraction of human alveolar macrophages |
Lokalisation |
Cytoplasm |
CD68
|
Zeta Corporation |
KP1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2071MS |
-
|
Host |
Mouse |
Klon |
KP1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil, lymph node, spleen. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Subcellular fraction of human alveolar macrophages |
Lokalisation |
Cytoplasm |
CD68
|
Zeta Corporation |
KP1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2071MT |
-
|
Host |
Mouse |
Klon |
514H12 |
Format |
TCS |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:40 - 1:80 |
Isotyp |
Mouse IgG2a |
Verdünnung |
Fusion protein corresponding to external domain of human CD68 |
CD68 (Macrosialin, Macrophage Antigen)
|
Zytomed Systems GmbH |
514H12 |
100 µl |
TCS |
RUO |
603-1332 |
-
|
Host |
Rat |
Klon |
FA-11 |
Format |
Purified |
Methode |
FL |
Isotyp |
Rat IgG2a |
CD68 (Macrosialin, Macrophage Antigen) - FITC
|
Zytomed Systems GmbH |
FA-11 |
50 µg |
Purified |
RUO |
603-1333C |
-
|
Host |
Mouse |
Klon |
Ki-M7 |
Format |
Purified |
Methode |
FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Cell suspensions of human lymph node |
CD68 (Macrosialin, Macrophage Antigen) - FITC
|
Zytomed Systems GmbH |
Ki-M7 |
100 Tests |
Purified |
RUO |
603-1334C |
-
|
Host |
Mouse |
Klon |
H68.4 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Bone marrow |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 |
Lokalisation |
Cell membrane, cytoplasm |
CD71
|
Biocare Medical |
H68.4 |
0.1 ml |
Concentrate |
CD/IVD |
ACI3110A |
-
|
Host |
Mouse |
Klon |
H68.4 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Bone marrow |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 |
Lokalisation |
Cell membrane, cytoplasm |
CD71
|
Biocare Medical |
H68.4 |
0.5 ml |
Concentrate |
CD/IVD |
ACI3110B |
-
|
Host |
Mouse |
Klon |
H68.4 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Bone marrow |
Verdünnung |
- |
Isotyp |
IgG1 |
Lokalisation |
Cell membrane, cytoplasm |
CD71
|
Biocare Medical |
H68.4 |
6 ml |
Ready-to-use |
CD/IVD |
API3110AA |
-
|
Host |
Mouse |
Klon |
ZM136 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Spleen, bone marrow |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1/κ |
Verdünnung |
Recombinant fragment of human TFRC receptor |
Lokalisation |
Cytoplasm |
CD71
|
Zeta Corporation |
ZM136 |
1 ml |
Concentrate |
CE/IVD |
Z2685ML |
-
|
Host |
Mouse |
Klon |
ZM136 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Spleen, bone marrow |
Verdünnung |
- |
Isotyp |
IgG1/κ |
Verdünnung |
Recombinant fragment of human TFRC receptor |
Lokalisation |
Cytoplasm |
CD71
|
Zeta Corporation |
ZM136 |
7 ml |
Concentrate |
CE/IVD |
Z2685MP |
-
|
Host |
Mouse |
Klon |
ZM136 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Spleen, bone marrow |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1/κ |
Verdünnung |
Recombinant fragment of human TFRC receptor |
Lokalisation |
Cytoplasm |
CD71
|
Zeta Corporation |
ZM136 |
0.5 ml |
Concentrate |
CE/IVD |
Z2685MS |
-
|
Host |
Mouse |
Klon |
ZM136 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Spleen, bone marrow |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1/κ |
Verdünnung |
Recombinant fragment of human TFRC receptor |
Lokalisation |
Cytoplasm |
CD71
|
Zeta Corporation |
ZM136 |
0.1 ml |
Concentrate |
CE/IVD |
Z2685MT |
-
|
Host |
Mouse |
Klon |
LN-2 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
CD74
|
Diagnostic Biosystems |
LN-2 |
1 ml |
Concentrate |
CE/IVD |
MOB168 |
-
|
Host |
Mouse |
Klon |
LN-2 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
CD74
|
Diagnostic Biosystems |
LN-2 |
0.1 ml |
Concentrate |
CE/IVD |
MOB168-01 |
-
|
Host |
Mouse |
Klon |
LN-2 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
CD74
|
Diagnostic Biosystems |
LN-2 |
0.5 ml |
Concentrate |
CE/IVD |
MOB168-05 |
-
|
Host |
Mouse |
Klon |
LN-2 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
CD74
|
Diagnostic Biosystems |
LN-2 |
6 ml |
Ready-to-use |
CE/IVD |
PDM033 |
-
|
Host |
Mouse |
Klon |
LN-1 |
Format |
Purified |
Methode |
F, P, FL |
Vorbehandlung |
Trypsin, Pronase |
Positivkontrolle |
Human Tonsil |
Isotyp |
Mouse IgM |
Verdünnung |
Human lymphocytes and SU-DHL4 cell line |
CD75s
|
Zytomed Systems GmbH |
LN-1 |
1 ml |
Purified |
RUO |
603-1354 |
-
|
Host |
Mouse |
Klon |
HM57 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:15 - 1:30 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cell Membrane |
CD79a
|
Diagnostic Biosystems |
HM57 |
1 ml |
Concentrate |
CE/IVD |
MOB118 |
-
|
Host |
Mouse |
Klon |
HM57 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:15 - 1:30 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cell Membrane |
CD79a
|
Diagnostic Biosystems |
HM57 |
0.1 ml |
Concentrate |
CE/IVD |
MOB118-01 |
-
|
Host |
Mouse |
Klon |
HM57 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:15 - 1:30 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cell Membrane |
CD79a
|
Diagnostic Biosystems |
HM57 |
0.5 ml |
Concentrate |
CE/IVD |
MOB118-05 |
-
|
Host |
Mouse |
Klon |
HM47/A9 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
CD79a
|
Diagnostic Biosystems |
HM47/A9 |
1 ml |
Concentrate |
CE/IVD |
MOB242 |
-
|
Host |
Mouse |
Klon |
HM47/A9 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
CD79a
|
Diagnostic Biosystems |
HM47/A9 |
0.1 ml |
Concentrate |
CE/IVD |
MOB242-01 |
-
|
Host |
Mouse |
Klon |
HM47/A9 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
CD79a
|
Diagnostic Biosystems |
HM47/A9 |
0.5 ml |
Concentrate |
CE/IVD |
MOB242-05 |
-
|
Host |
Mouse |
Klon |
HM47/A9 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
CD79a
|
Diagnostic Biosystems |
HM47/A9 |
6 ml |
Ready-to-use |
CE/IVD |
PDM125 |
-
|
Host |
Mouse |
Klon |
HM47/A9 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
CD79a
|
Diagnostic Biosystems |
HM47/A9 |
25 ml |
Ready-to-use |
CE/IVD |
PDM125-25 |
-
|
Host |
Rabbit |
Klon |
SP18 |
Format |
Ready-to-use |
Reaktivität |
DG, PG, BV |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cell Membrane |
CD79a
|
Zytomed Systems GmbH |
SP18 |
6 ml |
Ready-to-use |
RUO |
RBG029 |
-
|
Host |
Rabbit |
Klon |
SP18 |
Format |
Concentrate |
Reaktivität |
DG, PG, BV |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cell Membrane |
CD79a
|
Zytomed Systems GmbH |
SP18 |
1 ml |
Concentrate |
RUO |
RBK029 |
-
|
Host |
Rabbit |
Klon |
SP18 |
Format |
Concentrate |
Reaktivität |
DG, PG, BV |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cell Membrane |
CD79a
|
Zytomed Systems GmbH |
SP18 |
0.5 ml |
Concentrate |
RUO |
RBK029-05 |
-
|
Host |
Mouse |
Klon |
MEM-233 |
Format |
Purified |
Methode |
WB, IP, FL |
Isotyp |
Mouse IgG1 |
CD80
|
Zytomed Systems GmbH |
MEM-233 |
100 µg |
Purified |
RUO |
603-1373 |
-
|